Project Grant R01CA286036

Award Date 7/3/24

Completion Date 6/30/29

Dollars Obligated $2.3M

Federal Agency

National Cancer Institute

Awardee

The Children's Hospital Corporation (Z1L9F1MM1RY3)

Federal Grant Program

93.395

Assistance Type

Project Grant

Place of Performance

Boston, MA 02115, USA

Similar Awards

Project Grant R15CA293657
The project "ENGINEERING NATURAL KILLER CELLS TO TARGET ACUTE MYELOID LEUKEMIA WITH HLA-DR LOSS" is being funded by a $429,000 Project Grant from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) awarded to Western University of Health Sciences in California. The goal of this 3-year research project is to develop a novel chimeric antigen receptor (CAR) natural killer (NK) cell therapy that can specifically target acute myeloid leukemia (AML) with loss of the...
Project Grant R01CA291796
The National Cancer Institute (NCI) awarded a $402,600 Project Grant under the Cancer Treatment Research program (CFDA 93.395) to the Sloan-Kettering Institute for Cancer Research to develop novel chimeric antigen receptor (CAR) T-cell therapies targeting the U5 small nuclear ribonucleoprotein (U5 snRNP) complex for the treatment of acute myeloid leukemia (AML). The primary goals of this 5-year project are to develop these CAR T-cell therapies and investigate the mechanism by which U5 snRNP is...
Project Grant R01CA292084
This $683,472 Project Grant awarded by the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) supports the development of a novel targeted therapy for acute myeloid leukemia (AML). The principal investigators at the University of Cincinnati are conducting preclinical research to evaluate a differentiation-inducing agent (HOSU-53) that targets the mitochondrial enzyme DHODH. The goal is to promote AML cell differentiation, activate the immune system, and induce ferroptosis to...
Project Grant R41AI192172
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research Federal Grant Program (CFDA 93.855), provides $305,855 to Aleutian Therapeutics, Inc. to develop a novel gene editing platform that enables allogeneic pluripotent stem cell (PSC) therapies to evade host immune system recognition. The goal is to overcome key barriers to making PSC-based regenerative therapies, such as those for type 1 diabetes, more...
Project Grant R01CA288731
This Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides $439,644 to The Leland Stanford Junior University to conduct functional studies on human acute myeloid leukemia (AML) stem cells. The key objectives are to: 1) Investigate the relationship between specific genetic mutations and AML stem cell frequency, disease initiation, and disease maintenance by correcting mutations in primary AML cells and AML-induced pluripotent stem cells (iPSCs);...
Project Grant R21CA296748
This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $434,361.00 to Seattle Children's Hospital, doing business as Seattle Children's Research Institute, to develop a multispecific T cell engaging therapy for the treatment of mixed phenotype acute leukemia (MPAL). MPAL is a high-risk leukemia subtype that presents with both myeloid (e.g. CD33) and lymphoid (e.g. CD19) surface antigens, resulting in lower cure rates compared to...
Project Grant K22CA285837
This $194,688 Project Grant award from the National Cancer Institute (CFDA 93.398 Cancer Research Manpower program) supports research by Indiana University Indianapolis to investigate the role of the GATA2 gene in acute myeloid leukemia (AML) and the MonoMAC syndrome. The key objectives are to: 1) Define the genes regulated by the normal GATA2 protein and how their expression is altered by AML- and MonoMAC-associated GATA2 mutations, using a novel mouse model and overexpression studies in...
Project Grant R50CA293244
The University of Kansas Medical Center Research Institute, Inc. was awarded a $135,949 Project Grant from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395) to address barriers to enrolling patients in precision medicine clinical trials for acute myeloid leukemia (AML). The key objectives are to: 1) develop rapid in-house molecular testing capabilities to enable broader patient access to precision medicine trials, and 2) conduct community and patient...
Project Grant R43CA295241
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $400,000 to Kure Ai Inc. to develop a novel CAR-T cell therapy product targeting the MR1 antigen expressed on the surface of various tumor cells, including acute myeloid leukemia (AML) and glioblastoma. The key objectives are to: 1) assess MR1 expression in primary patient AML and glioblastoma samples, 2) perform mouse efficacy studies using AML and glioblastoma models, and 3)...
Project Grant R01CA299332
This Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides funding to Case Western Reserve University to conduct research aimed at understanding the fundamental biological mechanisms of acute myeloid leukemia (AML) and developing new therapeutic approaches. The $491,357 award supports investigations into using proteasome inhibitors and an mTORC1 activator molecule to induce metabolic stress and resensitize AML cells to treatment, particularly...

MULTIPLEX EPITOPE EDITING TO ENABLE NOVEL IMMUNOTHERAPIES FOR ACUTE MYELOID LEUKEMIA - PROJECT SUMMARY WHILE IMMUNOTHERAPIES HAVE PROVED COMPELLING EFFICACY AGAINST OTHER LEUKEMIAS, THEIR APPLICATION FOR ACUTE MYELOID LEUKEMIA (AML) IS STILL HAMPERED BY THE ABSENCE OF TUMOR-RESTRICTED TARGETS. THE MOST SUITABLE AML TARGETS ARE SHARED WITH HEALTHY HEMATOPOIETIC STEM/PROGENITOR CELLS (HSPCS) OR MATURE MYELOID CELLS, LEADING TO ON-TARGET/OFF-TUMOR TOXICITY AND IMPAIRMENT OF HEMATOPOIETIC RECONSTITUTION. TO ADDRESS THIS ISSUE, WE HYPOTHESIZED THAT EPITOPE-ENGINEERING OF DONOR HSPCS USED FOR CONVENTIONAL BONE MARROW TRANSPLANTATION CAN ENDOW HEMATOPOIETIC LINEAGES WITH SELECTIVE RESISTANCE TO CAR-T OR MONOCLONAL ANTIBODIES (MAB), WITHOUT AFFECTING PROTEIN FUNCTION OR REGULATION. THIS STRATEGY ALLOWS TARGETING GENES ESSENTIAL FOR LEUKEMIA SURVIVAL REGARDLESS OF SHARED EXPRESSION ON HSPCS, THUS REDUCING THE RISK OF TUMOR IMMUNE ESCAPE BY ANTIGEN DOWNREGULATION/LOSS. WE HAVE ALREADY IDENTIFIED SINGLE AMINO-ACID (AA) CHANGES THAT ABROGATE THE BINDING OF THERAPEUTIC MAB TARGETING FLT3, CD123, AND KIT AND OPTIMIZED A BASE-EDITING APPROACH TO INTRODUCE THEM INTO CD34+ HSPCS, WHICH RETAIN LONG-TERM ENGRAFTMENT AND MULTILINEAGE DIFFERENTIATION CAPACITY. WE CONFIRMED THE IN VIVO RESISTANCE OF EPITOPE-EDITED HEMATOPOIESIS TO CAR-T TREATMENT AND THE CONCOMITANT ERADICATION OF PATIENT-DERIVED AML XENOGRAFTS (CASIRATI ET AL., NATURE 2023). HERE, WE WILL CAPITALIZE ON THESE ACHIEVEMENTS AND EXPLOIT STATE-OF-THE-ART GENETIC ENGINEERING TOOLS AND IN VIVO MODELING WITH THE OBJECTIVES TO I) GENERATE AND FUNCTIONALLY VALIDATE "STEALTH" FLT3, KIT, AND IL3RA GENES BY MULTIPLEX BASE-EDITING; II) IDENTIFY THE BEST- PERFORMING CAR CONFIGURATION FOR MULTI-AG TARGETING ON AML SAMPLES AND III) VALIDATE RESISTANCE OF EDITED HSPC TO NEW IMMUNOTHERAPIES DIRECTED AGAINST THESE TARGETS. THIS PROJECT WILL PROVIDE FUNDAMENTAL ADVANCEMENT OF NEW AND MORE EFFECTIVE IMMUNOTHERAPY APPROACHES FOR AML THAT SHOULD ADDITIONALLY HAVE BROAD APPLICABILITY TO SEVERAL OTHER HEMATOPOIETIC MALIGNANCIES.

Posted 7/3/24

Mod #	Federal Obligation	Date
Not listed	$721.9k	6/12/25
Not listed	$780.4k	7/3/24
Not listed	$780.4k	7/3/24